An Open Study of ASP8273 in Patients With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations

Summary

Purpose of the study is to determine the following in patients with non-small cell lung cancer (NSCLC) harboring EGFR activating mutations. * the safety and tolerability of ASP8273. * the pharmacokinetics (PK) of ASP8273. * the antitumor activity of ASP8273.

Timeline

Start

2014-01-23

Primary completion

2016-01-15

Completion

2017-06-14

Drugs

Indications